#1 Clinical Trials Search in Europe

GSK3862995B

Clinical trials are investigating GSK3862995B in people with bronchiectasis. These studies look at how well it works, how safe it is, and how the body handles repeat doses. The main trial is in adults 18 to 85 years old with recurrent exacerbations or uncontrolled symptoms.

Table of contents

Trial overview

The available clinical trial of GSK3862995B is an interventional study in bronchiectasis. It is designed to compare GSK3862995B with placebo and to assess efficacy, safety, immunogenicity, and pharmacokinetics.[1]

The study is authorised and listed as Phase 2.[1]

Who is being studied

This study includes participants with bronchiectasis who are 18 to 85 years old, inclusive.[1]

The trial focuses on adults with recurrent exacerbations or uncontrolled symptoms, which means people who keep having flare-ups or do not have their symptoms well controlled.[1]

What the study measures

The main outcome is the percentage reduction in the annualized exacerbation rate on GSK3862995B versus placebo.[1]

This outcome is assessed in adult patients with bronchiectasis and recurrent exacerbations or uncontrolled symptoms, assuming no study treatment discontinuation, no change in maintenance standard of care, and no use of prohibited medications.[1]

In simple terms, the researchers want to know whether people taking GSK3862995B have fewer flare-ups over a year than people taking placebo.[1]

Trial design and treatment comparison

The study compares GSK3862995B with placebo, and the intervention is given subcutaneously, meaning under the skin.[1]

The trial also includes 5% Dextrose Injection as part of the listed interventions.[1]

Because this is an interventional study, researchers actively give the study treatment and then measure the results over time.[1]

Trial phase and size

This is a Phase 2 trial, which usually means the study is looking more closely at whether a treatment may help and continuing to monitor safety.[1]

The planned enrollment is 363 participants.[1]

The trial status is authorised.[1]

Patient-friendly terms

  • Bronchiectasis is a long-term lung disease where the airways stay widened and can collect mucus, which may lead to repeated infections and symptoms.

  • Exacerbation means a flare-up or worsening of symptoms.

  • Placebo is a look-alike treatment without the active study drug, used for comparison.

  • Pharmacokinetics means how the body handles a treatment after it is given.

  • Immunogenicity means whether the body makes an immune response against the treatment.

Trial ID Phase Condition studied Status Enrollment
2025-522892-27-00 Phase 2 Bronchiectasis Authorised 363

FAQ

  • What condition is being studied with GSK3862995B? The trial is studying bronchiectasis, a long-term lung condition. It focuses on adults who have repeated flare-ups or symptoms that are not well controlled.
  • Who can take part in the study? The study includes participants with bronchiectasis who are 18 to 85 years old. The trial description also says it is for adults with recurrent exacerbations or uncontrolled symptoms.
  • What is the main goal of the trial? The main goal is to compare GSK3862995B with placebo. The study is looking at efficacy, safety, immunogenicity, and pharmacokinetics.
  • What does immunogenicity mean? Immunogenicity means whether the body makes an immune response against the study treatment. This can help researchers understand how the treatment is tolerated over time.
  • What phase is the trial? This is a Phase 2 trial. Phase 2 studies usually look more closely at whether a treatment may help a condition and continue checking safety.

Ongoing Clinical Trials on GSK3862995B

  • A study testing GSK3862995B compared to placebo for safety and effectiveness in adults aged 18 to 85 years with bronchiectasis

    Recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Denmark France Germany Italy Poland Spain

Glossary

  • Bronchiectasis: A long-term lung condition where the airways are widened and can collect mucus, which may lead to repeated chest infections and symptoms.
  • Exacerbation: A flare-up or worsening of a disease. In this trial, it refers to worsening bronchiectasis symptoms.
  • Placebo: A treatment that looks like the study drug but does not contain the active study treatment. It helps researchers compare results fairly.
  • Efficacy: How well a treatment works for the condition being studied.
  • Safety: Information about how well a treatment is tolerated and whether it causes problems during the study.
  • Immunogenicity: Whether the body reacts to the study treatment by making an immune response.
  • Pharmacokinetics: How the body absorbs, moves, and removes a treatment over time.
  • Subcutaneous: Given under the skin.
  • Interventional study: A clinical study where researchers give a treatment and then measure the results.
  • Annualized exacerbation rate: The number of flare-ups counted over one year, used to measure how often symptoms worsen.
  • Maintenance SOC: Maintenance standard of care, meaning the regular treatment a participant is already using to keep the condition under control.

References